Rating Change
Morgan Stanley reiterated its Overweight rating on BridgeBio Oncology Therapeutics Inc. (NASDAQ:BBOT) on October 21, 2026.
reiterateNASDAQ:BBOT
Morgan Stanley Reiterates Overweight Rating on BridgeBio Oncology Therapeutics Inc. (BBOT)
Morgan Stanley reiterated its Overweight rating on BridgeBio Oncology Therapeutics Inc. (NASDAQ:BBOT) on October 21, 2026.
At publication ·
What changed
BridgeBio Oncology Therapeutics Inc. (NASDAQ:BBOT) · reiterate
- Firm
- Morgan Stanley
- Rating
- Overweight to Overweight
- Price at event
- $2.68
- Market capitalization
- $1.0B
At a glance
Key takeaways
- Morgan Stanley reiterated an Overweight rating on BridgeBio Oncology (BBOT) on October 21, 2026, with the stock trading at $2.68 and a market cap of $1.0 billion.
Market Context
BridgeBio Oncology Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $2.68 with a market capitalization of $1.0B. The stock has declined 75.6% over the past 52 weeks.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for BridgeBio Oncology Therapeutics Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for BridgeBio Oncology Therapeutics Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 21, 2026 | Morgan Stanley | Overweight | N/A |
| Oct 20, 2026 | Oppenheimer | Outperform | N/A |
| Sep 11, 2026 | JP Morgan | Overweight | N/A |
| Sep 10, 2026 | Leerink Partners | Outperform | N/A |
| Sep 09, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View BBOT Stock Page
Frequently Asked Questions
What does the Overweight rating mean for BBOT?
A rating of Overweight from Morgan Stanley reflects the analyst's outlook on BridgeBio Oncology Therapeutics Inc. (NASDAQ:BBOT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BBOT forecast page.